|
Clinical features
|
|
Females (n, (%))
|
60 (90.9)
|
12 (54.5)
|
|
Age (median (IQR))
|
36.3 (29.8–50.3)
|
62.0 (44.0–70.5)
|
|
Disease duration (median (IQR))
|
7.9 (2.6–14.3)
|
1.5 (0–6.5)
|
|
Disease activity
|
|
SLEDAI-2Ka (n = 65) (median (IQR))
|
12.0 (7.0–16.0)
|
–
|
|
BVAS (n = 17) (median (IQR))
|
–
|
15.0 (10.5–22.5)
|
|
Rituximab treatment regimens
|
|
375 mg/m2 × 4 weekly infusions (n, %)
|
38 (57.6)
|
5 (22.7)
|
|
1 g 2 weeks apart (n, %)
|
24 (36.4)
|
13 (59.1)
|
|
500 mg 2 weeks apart (n, %)
|
4 (6.1)
|
3 (13.6)
|
|
Concomitant treatments
|
|
IV cyclophosphamide (n, %)
|
36 (54.5)
|
10 (45.4)
|
|
IV 6-methylprednisolone (n, %)
|
37 (56.1)
|
4 (18.2)
|
